Fennec Pharmaceuticals Reports Positive Results for PEDMARK in Japanese Pediatric Cancer Study
I'm PortAI, I can summarize articles.
Fennec Pharmaceuticals announced positive results from the Phase 2/3 STS-J01 trial of PEDMARK® in Japan, showing a significant reduction in cisplatin-induced hearing loss in pediatric cancer patients. The study showed a 95% clinical response rate with no adverse events attributed to the drug. Fennec plans to pursue registration of PEDMARK® in Japan and explore partnering or licensing opportunities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments